Ken Griffin Aim Immuno Tech Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.4 - $0.56 $13,607 - $19,050	34,018 New	34,018 $14,000
Q1 2023 May 15, 2023	SELL	$0.32 - $0.77 $12,906 - $31,056	-40,333 Reduced 57.41%	29,924 $12,000
Q4 2022 Feb 14, 2023	BUY	$0.31 - $0.6 $21,779 - $42,154	70,257 New	70,257 $21,000
Q1 2022 May 16, 2022	SELL	$0.67 - $1.18 $27,504 - $48,441	-41,052 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$0.92 - $1.96 $57,252 - $121,972	-62,231 Reduced 60.25%	41,052 $37,000

Q1 2021 May 17, 2021	BUY	$1.88 - $2.82 $194,172 - $291,258	103,283 New	103,283 $234,000
Q4 2020 Feb 16, 2021	SELL	$1.68 - $2.45 $27,809 - $40,554	-16,553 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.77 - $3.88 $29,298 - $64,225	16,553 New	16,553 $36,000

4.11M

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $19.2M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.